1. The essential consequences of polymorphism in the pharmaceutical field

Previous articles and have already given a glimpse of the main consequences expected in the pharmaceutical sector.

They mainly concern :

• dissolution kinetics and, possibly, bioavailability;

• the manufacturability of the active ingredient and the finished product;

• the stability of the latter two.

These areas have already been more or less developed, so we'll confine ourselves here to briefly touching on certain aspects.